Atopic Dermatitis (Eczema) and Topical Corticosteroids (Topical Steroids)

Deep Dive

From a western clinical perspective, atopic dermatitis is driven by two intertwined problems: a compromised epidermal barrier and immune dysregu... From a western clinical perspective, atopic dermatitis is driven by two intertwined problems: a compromised epidermal barrier and immune dysregulation skewed toward type 2 inflammation. This combination allows irritants, microbes, and allergens to penetrate, increasing antigen presentation and cytokine release that perpetuate itch and inflammation. Topical corticosteroids (TCS) address the inflammatory arm directly by activating cutaneous glucocorticoid receptors and down‑regulating pro‑inflammatory pathways. In practice, they are selected by potency according to age, body site, and severity—milder agents on thin skin and in children; stronger agents for short bursts on lichenified plaques. With appropriate use, most patients experience clinically meaningful relief of erythema, edema, and pruritus within days, often achieving control within 1–2 weeks. Evidence also supports proactive, intermittent use on previously involved areas to prevent relapses, in tandem with daily emollients that restore barrier function. Risk management is integral. The likelihood of cutaneous atrophy, telangiectasia, striae, and other local effects rises with higher potency, prolonged continuous use, and application to thin or occluded skin. Systemic absorption sufficient to suppress the hypothalamic–pituitary–adrenal axis is unusual under guideline‑concordant regimens but can occur, particularly in young children when large areas or wet‑wraps are involved. Clinical teams prioritize the lowest effective potency for the shortest necessary duration, reassess after acute control, and pivot to steroid‑sparing strategies—topical calcineurin inhibitors, PDE‑4 or topical JAK inhibitors—for maintenance or for sensitive areas like the face and folds. For moderate‑to‑severe disease refractory to optimized topical care, phototherapy and highly effective systemic options (dupilumab, tralokinumab, oral JAK inhibitors) provide durable control and reduce dependence on TCS. Two controversies require nuance. First, topical steroid withdrawal (TSW) or “red skin syndrome” is recognized anecdotally and in case series, especially after prolonged daily use of potent agents; robust epidemiologic data are lacking, leaving prevalence and pathophysiology uncertain. Second, steroid phobia is widespread and contributes to undertreatment and ongoing inflammation. Shared decision‑making—clear instructions, safety monitoring, and discussion of alternatives—helps patients balance benefits and risks. Pediatric care warrants special attention to absorption, body‑site differences, and caregiver education, with referral to dermatology for severe, recurrently infected, or treatment‑resistant disease.